Drug intelligence / Profile preview

Esavasone

Development stage: Unknown
Lead developer: Praise Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

**Esavasone** is a topical fixed-dose lotion marketed by Praise Pharma for seborrheic dermatitis, dandruff, and fungal skin conditions with associated inflammation and pruritus. It contains ketoconazole nitrate 2% w/v, an imidazole antifungal that inhibits fungal ergosterol synthesis through inhibition of lanosterol 14-alpha-demethylase, and clobetasone butyrate 0.05% w/v, a topical corticosteroid that activates glucocorticoid receptors to reduce inflammatory signaling, erythema, and itching. ([praisepharma.com](https://www.praisepharma.com/products/anti-fungal_esavasone-lotion.html))

Brand names: Esavasone

Targets

GR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on Esavasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esavasone.

Explore the full profile